Archives
-
Nelfinavir Mesylate: Reliable Cell Assays
2026-08-13
A scenario-driven guide to using Nelfinavir Mesylate (SKU A3653) in HIV-1, cell viability, cytotoxicity, and ferroptosis workflows. It connects reported nanomolar activity with practical stock preparation, controls, assay interpretation, and vendor-selection criteria.
-
CAPE NF-κB Workflows in Neurodegeneration
2026-08-13
Caffeic Acid Phenethyl Ester (CAPE) provides a practical chemical probe for separating NF-κB-dependent inflammation from Fyn–Stat3 signaling in neurodegeneration models. This guide converts the reference study’s zebrafish strategy into dose-aware workflows and extends the same pathway logic to angiogenesis, VEGF, and tumor-invasion assays.
-
Nelfinavir Mesylate: Reliable Cell Assays
2026-08-12
This scenario-driven guide shows how Nelfinavir Mesylate (SKU A3653) can support reproducible antiviral, viability, and ferroptosis-related workflows. It links product specifications with published evidence while addressing formulation, controls, interpretation, and vendor-selection decisions.
-
Ellagic Acid: An Assay-First CK2 Research Guide
2026-08-12
Ellagic acid is a selective ATP-competitive CK2 inhibitor for mechanistic cancer biology research. This assay-first guide connects CK2 pharmacology with senescence studies while emphasizing solvent control, orthogonal validation, and responsible interpretation.
-
Trifluoperazine 2HCl: Causal Assay Design
2026-08-11
Trifluoperazine 2HCl is a dopamine D2 receptor inhibitor suited to rigorous receptor, pathway, and phenotype studies. This guide develops a causal assay framework that separates target engagement from downstream effects across neuropharmacology, macrophage biology, and cancer research.
-
0.4% Trypan Blue Solution: Practical Cell Counting
2026-08-11
0.4% Trypan Blue Solution supports rapid cell viability measurement, cell counting, and live/dead cell discrimination by staining dead or membrane-damaged cells blue. It is intended for research workflows such as cell culture and cytotoxicity assays, not for diagnostic, clinical, or medical use.
-
Linoleic Acid (C18:2): Practical Lab Guide
2026-08-10
Linoleic Acid (SKU C3108) provides a defined omega-6 fatty acid input for oxidative stress assays, membrane studies, erythrocyte injury workflows, cell migration assays, and nutritional deficiency models. It is water-insoluble, requires an ethanol- or DMSO-based preparation, and is best used with freshly prepared solutions rather than long-term stored stocks.
-
BIIE 0246: Mapping NPY Signals in Cardiac Models
2026-08-09
BIIE 0246 is a selective neuropeptide Y Y2 receptor antagonist that can help researchers separate Y2R-dependent signaling from the Y1R pathway implicated in adipose-neural cardiac arrhythmia. This article develops an assay-centered framework for interpreting that distinction across neurobiology, feeding, and neurocardiac models.
-
Oxidation Shapes Hazelnut Protein Gels
2026-08-08
Jiang and colleagues systematically compared AAPH, malondialdehyde, and hydrogen peroxide as distinct oxidation modes for hazelnut proteins. Their results show that oxidation chemistry, dose, and protein assembly state jointly determine interfacial functionality and gel microstructure, providing a useful framework for designing food-protein oxidation studies.
-
GANT61 in ALK-Positive ALCL: Hh–PIK3IP1–Akt Axis
2026-08-07
A 2026 Annals of Hematology study identifies GANT61-mediated Gli1 inhibition as a potential way to suppress ALK-positive anaplastic large cell lymphoma through the Hh–PIK3IP1–Akt signaling axis. Its integrated use of proliferation, flow cytometry, transcriptomic, qRT-PCR, and western blot analyses links cell-cycle arrest and apoptosis with altered pathway activity, while also highlighting the need for further in vivo and causal validation.
-
Targeting GOT1 Rewires Glutamine Metabolism in Pancreatic Ca
2026-08-07
The referenced study identifies ziprasidone as a novel inhibitor of GOT1, disrupting glutamine metabolism and redox homeostasis in pancreatic ductal adenocarcinoma (PDAC) cells. This approach highlights GOT1 as a promising therapeutic target, with direct impact on tumor proliferation and survival.
-
EGTA (3,12-bis(carboxymethyl)-6,9-dioxa-3,12-diazatetradecan
2026-08-06
This article addresses real-world laboratory challenges in cell viability and calcium signaling research, focusing on the application of EGTA (3,12-bis(carboxymethyl)-6,9-dioxa-3,12-diazatetradecane-1,14-dioic acid), APExBIO SKU B7195. By integrating scenario-driven questions and evidence-based answers, we demonstrate how this high-purity, well-characterized aminopolycarboxylic acid calcium chelator enhances data reproducibility and experimental confidence.
-
ARL4C Drives Synoviocyte Proliferation and RA Progression
2026-08-06
This study utilizes single-cell and bulk transcriptomic analyses to uncover ARL4C as a critical regulator of fibroblast-like synoviocyte (FLS) proliferation and macrophage polarization in rheumatoid arthritis (RA). The findings refine our molecular understanding of RA pathogenesis and highlight ARL4C as a promising therapeutic target and experimental axis for future cell cycle and genotoxicity research.
-
Chlorambucil in Translational Oncology: Mechanisms, Metrics,
2026-08-05
This thought-leadership article synthesizes mechanistic insights and actionable strategies for translational researchers using chlorambucil—a nitrogen mustard alkylating agent pivotal to both chronic lymphocytic leukemia treatment and preclinical research. By bridging molecular mechanisms, in vitro assay advances, and best practices, it empowers oncology investigators to optimize study design, interpret cytotoxicity data with precision, and future-proof their translational workflows.
-
RNA Pol II Inhibition Triggers Apoptosis via Non-Transcripti
2026-08-05
Harper et al. (2025) reveal that cell death from RNA polymerase II (Pol II) inhibition is not simply a consequence of lost transcription but is instead triggered by the loss of hypophosphorylated RNA Pol IIA, activating an active apoptotic pathway. This mechanistic insight challenges longstanding assumptions about transcriptional blockade lethality and has direct implications for the design of epigenetic and apoptosis-focused oncology research.